Taking aim at mutant genes to treat melanoma

After many years of standstill and unsuccessful attempts, therapeutic advances have significantly improved the survival of patients with melanoma.

Since 2010, there has been a massive paradigm shift in systemic melanoma therapy.

On target bullseye

Before this, no survival benefits had been demonstrated throughout a variety of clinical trials.

Prognosis for metastatic melanoma patients was desperate, with a median overall survival of only a few months.1

The introduction of both targeted therapy with specific kinase inhibitors and immunotherapy with selected checkpoint inhibitors have led to dramatic improvements in outcomes for some advanced melanoma patients.

Not only have significant